Spots Global Cancer Trial Database for angiogenesis
Every month we try and update this database with for angiogenesis cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL | NCT06086197 | Diffuse Large B... Diffuse Large B... | Anlotinib hydro... | 18 Years - | Zhejiang Cancer Hospital | |
| The PIONEER-01 Study of the Imagio Breast Imaging System | NCT01943916 | Breast Cancer | Imagio OA/US (U... Imagio gray sca... | 18 Years - | Seno Medical Instruments Inc. | |
| Micrometastases and Angiogenesis in Colon Cancer. Prognostic Value of VEGF. | NCT04145505 | Colorectal Canc... Angiogenesis | COLORECTAL CANC... | 18 Years - | Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | |
| Transarterial Chemoembolisation Plus Bevacizumab for Treatment of Hepatocellular Carcinoma | NCT00280007 | Hepatocellular ... | bevacizumab | 18 Years - 85 Years | Medical University of Vienna | |
| RGD-PET-CT in Cancer Angiogenesis | NCT01492192 | Carcinoma, Rena... | 18F-RGD-PET-CT ... | 18 Years - | Oxford University Hospitals NHS Trust | |
| BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors | NCT00095459 | Neoplasms | Bevacizumab BAY 43-9006 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Efficacy and Safety Study of M200(Volociximab in Combination With Liposomal Doxorubicin) | NCT00635193 | Ovarian Cancer,... | M200 (Volocixim... Liposomal Doxor... M200 (Volocixim... M200 (Volocixim... | 18 Years - | AbbVie | |
| MONET1-MOtesanib NSCLC Efficacy and Tolerability Study | NCT00460317 | Non-Small Cell ... | AMG 706 placebo paclitaxel carboplatin | 18 Years - | Amgen | |
| Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors | NCT01283945 | Solid Tumors | Lucitanib | 18 Years - | Servier | |
| The Efficacy and Safety of Endostar Combined With Taxane-based Regimens for HER-2-negative MBC Patients | NCT02865304 | Angiogenesis Breast Cancer | endostar | 18 Years - 70 Years | Fujian Cancer Hospital | |
| Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization | NCT00434109 | Neuroendocrine ... Islet Cell Tumo... | Sunitinib malat... Hepatic Artery ... | 18 Years - | H. Lee Moffitt Cancer Center and Research Institute | |
| GW786034 In Subjects With Locally Recurrent Or Metastatic Clear Cell Renal Cell Carcinoma | NCT00244764 | Carcinoma, Rena... | GW786034 Placebo | 21 Years - | GlaxoSmithKline | |
| Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer | NCT05595889 | Small Cell Lung... Angiogenesis Chemotherapy Ef... | Surufatinib Irinotecan | 18 Years - 80 Years | Fujian Cancer Hospital | |
| AVE0005 (VEGF Trap) in Patients With Recurrent Symptomatic Malignant Ascites | NCT00396591 | Ovarian Neoplas... | Aflibercept (zi... | 18 Years - | Sanofi | |
| The Efficacy and Safety of Endostar Combined With Taxane-based Regimens for HER-2-negative MBC Patients | NCT02865304 | Angiogenesis Breast Cancer | endostar | 18 Years - 70 Years | Fujian Cancer Hospital | |
| RGD-PET-CT in Cancer Angiogenesis | NCT01492192 | Carcinoma, Rena... | 18F-RGD-PET-CT ... | 18 Years - | Oxford University Hospitals NHS Trust | |
| The Impact of Intravenous Anaesthesia on Angiogenesis in Patients With Breast Cancer (TIVA/TCI-BC) | NCT02839668 | Breast Cancer | Lidocaine Sevoflurane TIVA-TCI Acetaminophen Tramadol Neostigmine Atropine BIS | 18 Years - 80 Years | Iuliu Hatieganu University of Medicine and Pharmacy | |
| The Mechanism of Sox4 Transcription in Regulation of Angiogenesis in Hepatocellular Carcinoma | NCT04296058 | Translational R... | microvessel den... | 20 Years - 85 Years | Chang Gung Memorial Hospital | |
| A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer | NCT00001446 | Prostatic Neopl... | thalidomide | - | National Institutes of Health Clinical Center (CC) | |
| PTC299 for Treatment of Advanced Cancer | NCT00704821 | Advanced Cancer | PTC299 Docetaxel | 18 Years - | PTC Therapeutics | |
| PTC299 and Hormonal Agent for Treatment of Metastatic Breast Cancer | NCT00508586 | Metastatic Brea... | PTC299 | 18 Years - | PTC Therapeutics | |
| Application of Proteome Profiler Antibody Arrays to Find Angiogenetic Predictors in Glioma Paitents. | NCT03225963 | Glioblastoma Mu... Angiogenesis | Chemoradiation ... | 20 Years - 85 Years | Taichung Veterans General Hospital | |
| Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors | NCT00777504 | Renal Cell Carc... Gastrointestina... | usage oral angi... stop oral angio... | 18 Years - | Radboud University Medical Center | |
| PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC | NCT04273100 | Hepatocellular ... | PD-1 mAb combin... | 18 Years - | Tianjin Medical University Cancer Institute and Hospital | |
| Collection of Blood, Bone Marrow, Tumor or Tissue Samples | NCT00043615 | Neoplasms Precancerous Co... | 18 Years - | National Institutes of Health Clinical Center (CC) | ||
| Efficacy Study of Revlimid® and Low Dose Continuously Administered Melphalan to Treat High Risk MDS | NCT00744536 | Myelodysplastic... Leukemia, Myelo... Angiogenesis | Lenalidomide an... | 18 Years - | Sunnybrook Health Sciences Centre | |
| Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors | NCT00777504 | Renal Cell Carc... Gastrointestina... | usage oral angi... stop oral angio... | 18 Years - | Radboud University Medical Center | |
| PTC299 for Treatment of Neurofibromatosis Type 2 | NCT00911248 | Neurofibromatos... | PTC299 | 18 Years - | PTC Therapeutics | |
| Efficacy of Hyperbaric Oxygen Therapy in Laryngectomy Patients | NCT00026975 | Laryngeal Cance... | Hyperbaric Oxyg... | 18 Years - | National Center for Complementary and Integrative Health (NCCIH) | |
| Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma | NCT00917384 | Gastric Cancer Adenocarcinoma | ramucirumab Placebo Best Supportive... | 18 Years - | Eli Lilly and Company | |
| Endostar Combination With Chemotherapy and EGFR-TKI in Lung Cancer Rechallenging Treatment After Acquired Resistance. | NCT02350361 | Lung Cancer | Recombinant hum... Placebo | 18 Years - 75 Years | Peking University Third Hospital | |
| Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN) | NCT04464122 | Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... | Somatostatin an... | 18 Years - 80 Years | University of Roma La Sapienza | |
| Angiogenic and EGFR Blockade With Curative Chemoradiation for Advanced Head and Neck Cancer | NCT00140556 | Head and Neck C... Pharynx Cancer | Chemoradiothera... Cisplatin Bevacizumab Erlotinib | 18 Years - | Duke University | |
| Evaluation of New Biomarkers Predictive of Efficacy Betablockers in PEComa and Vascular Pediatric Tumors | NCT02334930 | PEComa Hemangioma | Biopsy | - | University Hospital, Bordeaux | |
| The PIONEER-01 Study of the Imagio Breast Imaging System | NCT01943916 | Breast Cancer | Imagio OA/US (U... Imagio gray sca... | 18 Years - | Seno Medical Instruments Inc. | |
| PTC299 and Hormonal Agent for Treatment of Metastatic Breast Cancer | NCT00508586 | Metastatic Brea... | PTC299 | 18 Years - | PTC Therapeutics | |
| AZD7451 for Recurrent Gliomas | NCT01468324 | Glioblastoma Mu... | AZD7451 | 18 Years - 100 Years | National Institutes of Health Clinical Center (CC) | |
| The Combination of Anlotinib and Immune Checkpoint Inhibitors for Advanced NSCLC Patients With Muti-line Therapy | NCT04670107 | NSCLC Angiogenesis Immunotherapy | Anlotinib in co... | 18 Years - | The Affiliated Hospital of Qingdao University | |
| Exploratory Study of Effects of Radiation Therapy in Pediatric Patients With Central Nervous System Tumors | NCT01445288 | Diffuse Intrins... PNET Ependymoma Germinoma Medulloblastoma | 1 Month - 21 Years | National Institutes of Health Clinical Center (CC) | ||
| Impact of Bevacizumab on Symptom Burden and Neurological Deficits in Patients With Recurrent Glioblastoma | NCT04974983 | Glioblastoma Angiogenesis | Observation of ... | 18 Years - | University Hospital Regensburg | |
| Biomarker Analyses in Hepatocellular Carcinoma (HCC) Patients Treated With TheraSphere® | NCT03203837 | Hepatocellular ... | Plasma collecti... | 18 Years - | Northwestern University | |
| Ischemic Heart Disease in Male With Prostate Adenocarcinoma | NCT03474835 | Ischemic Heart ... Prostate Adenoc... | ISCHEMIC HEART ... | - | Dnipropetrovsk State Medical Academy | |
| Italian Study Of Validation Of Angiogenesis Polymorphisms In HCC Patients Treated With Sorafenib | NCT02786342 | Hepatocellular ... | blood sample co... | 18 Years - | Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori | |
| Study of Oral Lucitanib (E-3810), a Dual VEGFR-FGFR Tyrosine Kinase Inhibitor, in Patients With Solid Tumors | NCT01283945 | Solid Tumors | Lucitanib | 18 Years - | Servier | |
| Effect of Exercise Training on Angiogenesis and Cachexia in Lung Cancer Patients | NCT01136083 | Non-small-cell ... | Exercise traini... Usual care | 40 Years - 75 Years | National Taiwan University Hospital | |
| Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma | NCT04941274 | Kaposi Sarcoma | Abemaciclib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| The Role of the Novel 99mTc-NC100692 Tracer in Patients at High Risk or Known Breast Cancer | NCT01503697 | Breast Cancer Tumor Angiogene... | 18 Years - | Tel-Aviv Sourasky Medical Center | ||
| Dose-Dense Chemotherapy Plus Bevacizumab in High Risk Lymph Node Positive Breast Cancer: A Pilot Study | NCT00378638 | Breast Cancer | bevacizumab com... | 18 Years - | Chap, Linnea I., M.D. | |
| PF-03446962 in Relapsed or Refractory Urothelial Cancer | NCT01620970 | Transitional Ce... | PF03446962 | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| Surufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung Cancer | NCT05595889 | Small Cell Lung... Angiogenesis Chemotherapy Ef... | Surufatinib Irinotecan | 18 Years - 80 Years | Fujian Cancer Hospital | |
| PF-03446962 in Relapsed or Refractory Urothelial Cancer | NCT01620970 | Transitional Ce... | PF03446962 | 18 Years - | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano | |
| Ischemic Heart Disease in Male With Prostate Adenocarcinoma | NCT03474835 | Ischemic Heart ... Prostate Adenoc... | ISCHEMIC HEART ... | - | Dnipropetrovsk State Medical Academy | |
| Exercise in Breast Cancer Survivors | NCT01582685 | Breast Cancer Obesity | Exercise | 18 Years - | University of Mississippi Medical Center | |
| Subharmonic Imaging and Pressure Estimation for Monitoring Neoadjuvant Chemotherapy | NCT02115607 | Breast Cancer | Definity infusi... | 21 Years - | Thomas Jefferson University | |
| A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer | NCT00090545 | Prostate Cancer | BAY 43-9006 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Zometa and Circulating Vascular Endothelial Growth Factor (VEGF) in Breast Cancer Patients With Bone Metastasis | NCT00524849 | Metastatic Brea... Bone Metastases | Zoledronic acid Zoledronic acid | 18 Years - 75 Years | Fudan University | |
| Avastin (Bevacizumab) Plus Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) for Advanced Stage Hodgkin Lymphoma | NCT00722865 | Hodgkin Lymphom... | Avastin | 18 Years - | Massachusetts General Hospital | |
| Dose-Dense Chemotherapy Plus Bevacizumab in High Risk Lymph Node Positive Breast Cancer: A Pilot Study | NCT00378638 | Breast Cancer | bevacizumab com... | 18 Years - | Chap, Linnea I., M.D. | |
| Neo-adjuvant Therapy and the Effect on Synchronous Metastatic Growth | NCT00659022 | Colorectal Neop... Liver Neoplasms | immediate surge... neo-adjuvant tr... neoadjuvant tre... neo-adjuvant tr... | 18 Years - 80 Years | Radboud University Medical Center | |
| Radiation Therapy (XRT) and ZD6474 in Non-Small Cell Lung Cancer (NSCLC) | NCT00745732 | Non-Small Cell ... | ZD6474 (ZACTIMA... Radiation Thera... | 18 Years - | M.D. Anderson Cancer Center | |
| A Randomized Phase II Study of Oral Thalidomide in Patients With Hormone-Refractory Prostate Cancer | NCT00001446 | Prostatic Neopl... | thalidomide | - | National Institutes of Health Clinical Center (CC) | |
| A Phase I Study of Oral COL-3 (NSC-683551), a Matrix Metalloproteinase Inhibitor, in Patients With Refractory Metastatic Cancer | NCT00001683 | Lymphoma Melanoma Neoplasm Metast... Renal Cell Carc... | COL-3 | - | National Institutes of Health Clinical Center (CC) | |
| Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors | NCT00777504 | Renal Cell Carc... Gastrointestina... | usage oral angi... stop oral angio... | 18 Years - | Radboud University Medical Center | |
| The Mechanism of Sox4 Transcription in Regulation of Angiogenesis in Hepatocellular Carcinoma | NCT04296058 | Translational R... | microvessel den... | 20 Years - 85 Years | Chang Gung Memorial Hospital | |
| MONET1-MOtesanib NSCLC Efficacy and Tolerability Study | NCT00460317 | Non-Small Cell ... | AMG 706 placebo paclitaxel carboplatin | 18 Years - | Amgen | |
| BAY 43-9006 (Sorafenib) and Bevacizumab (Avastin) To Treat Solid Tumors | NCT00095459 | Neoplasms | Bevacizumab BAY 43-9006 | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT00445549 | Ovarian Neoplas... Fallopian Tube ... Peritoneal Neop... | Vandetanib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| TACE, Sorafenib and PD-1 Monoclonal Antibody in the Treatment of HCC | NCT04518852 | Hepatocellular ... Liver Neoplasms Digestive Syste... Sorafenib Molecular Mecha... Liver Diseases Antineoplastic ... Protein Kinase ... | TACE combined w... | 18 Years - | Sichuan Cancer Hospital and Research Institute | |
| Study of AVE0005 (VEGF Trap) in Patients With Chemoresistant Advanced Ovarian Cancer | NCT00327171 | Neoplasms Cancer of the O... | Aflibercept (zi... Aflibercept (zi... | 18 Years - | Sanofi | |
| A-RGEMOX in the Treatment of Early Relapsed/Refractory DLBCL | NCT06086197 | Diffuse Large B... Diffuse Large B... | Anlotinib hydro... | 18 Years - | Zhejiang Cancer Hospital | |
| Docetaxel, Thalidomide, Prednisone, and Bevacizumab to Treat Metastatic Prostate Cancer | NCT00089609 | Prostatic Neopl... | Docetaxel Thalidomide Prednisone bevacizumab polymorphism an... immunoenzyme te... laboratory biom... pharmacological... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors | NCT01445509 | Solid Tumors | Bevacizumab Dasatinib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Vandetanib to Treat Women With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | NCT00445549 | Ovarian Neoplas... Fallopian Tube ... Peritoneal Neop... | Vandetanib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN) | NCT04464122 | Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... Neuroendocrine ... | Somatostatin an... | 18 Years - 80 Years | University of Roma La Sapienza | |
| Nintedanib Plus EGFR TKI In EGFR-mutated Non-small Cell Lung Cancer Patients | NCT06071013 | Non-small Cell ... EGFR Gene Mutat... EGFR-TKI Resist... | Nintedanib, gef... | 20 Years - 70 Years | China Medical University Hospital | |
| The Effect of Radiotherapy and Temozolomide on the Tumor Vasculature and Stem Cells in Human High-grade Astrocytomas | NCT00473408 | Anaplastic Astr... Glioblastoma Mu... Tumor Angiogene... | Functional MRI ... Blood sample Tumor sample | 18 Years - | Haukeland University Hospital | |
| Study of Aflibercept And Modified FOLFOX6 As First-Line Treatment In Patients With Metastatic Colorectal Cancer | NCT00851084 | Colorectal Neop... Neoplasm Metast... | aflibercept oxaliplatin 5-FU Folinic Acid | 18 Years - | Sanofi | |
| The Efficacy and Safety of Endostar Combined With Taxane-based Regimens for HER-2-negative MBC Patients | NCT02865304 | Angiogenesis Breast Cancer | endostar | 18 Years - 70 Years | Fujian Cancer Hospital | |
| A Proof-of-concept Study to Assess the Ability of [18F]AH-111585 PET Imaging to Detect Tumours and Angiogenesis | NCT00565721 | High-grade Glio... Lung Cancer Head & Neck Can... Sarcoma Melanoma | Fluciclatide In... | 18 Years - | GE Healthcare | |
| Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors | NCT00777504 | Renal Cell Carc... Gastrointestina... | usage oral angi... stop oral angio... | 18 Years - | Radboud University Medical Center |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
